Ilmarinen Mutual Pension Insurance Co Buys 3,400 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ilmarinen Mutual Pension Insurance Co grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 42.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,400 shares of the biopharmaceutical company's stock after buying an additional 3,400 shares during the quarter. Ilmarinen Mutual Pension Insurance Co's holdings in Regeneron Pharmaceuticals were worth $8,121,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the last quarter. Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $36,000. Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $36,000. Finally, Private Wealth Management Group LLC increased its holdings in Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research report on Tuesday, February 4th. Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a report on Friday, January 10th. Finally, Piper Sandler dropped their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $966.88.

Regeneron Pharmaceuticals Trading Up 0.7 %

REGN stock traded up $3.70 during trading on Friday, reaching $550.09. The company had a trading volume of 452,359 shares, compared to its average volume of 704,420. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 52 week low of $525.99 and a 52 week high of $1,211.20. The business has a 50 day moving average of $662.80 and a 200 day moving average of $758.54. The company has a market cap of $60.14 billion, a P/E ratio of 14.36, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $11.86 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.64%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.